other material
confidence high
sentiment negative
materiality 0.80
Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones
Hepion Pharmaceuticals, Inc.
- Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.
- Stockholders receive CVR: $500K upon FDA approval of first NDA for Rencofilstat.
- Additional CVR payments: $1M if net sales exceed $350M; $3M if net sales exceed $750M.